© EQS Newswire
26.01.2024
1SXP
LISTED
XETR
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
News Preview
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
FY 2023: Revenues up 9% yoy to EUR 899m, EBITDA increase of 9% to EUR 239m, maintaining high EBITDA margin of 26.6%
Strategic shift towards strong-margin high-value solutions (HVS) further accelerated, representing 48% of full year revenues
For FY 2024, SCHOTT Pha......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2024
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für 2023 und setzt profitablen Wachstumskurs fort
News Preview
SCHOTT Pharma erreicht Jahresziele für 2023 und setzt profitablen Wachstumskurs fort
Geschäftsjahr 2023: Umsatzwachstum von 9 % gegenüber Vorjahr auf 899 Millionen Euro, EBITDA-Anstieg um 9 % auf 239 Millionen Euro, weiterhin hohe EBITDA-Marge von 26,6 %
Strategische Ausrichtung auf margenstarke High-Value-Lösungen weiter beschleunigt; Umsatzant......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2024
SRT
LISTED
XETRA
Sartorius erwartet für 2024 profitables Wachstum; Umsatz soll bis 2028 pro Jahr zweistellig steigen
News Preview
Göttingen, 26. Januar 2024
Sartorius erwartet für 2024 profitables Wachstum; Umsatz soll bis 2028 pro Jahr zweistellig steigen
Vorläufige Geschäftsergebnisse für das Jahr 2023 im Rahmen der Prognose: Umsatz wechselkursbereinigt -16,6 Prozent; operative EBITDA-Marge erreicht 28,3 Prozent
Nachfragebelebung in beiden Konzernsparten im 4. Quartal:......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
26.01.2024
SRT
LISTED
XETRA
Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028
News Preview
Göttingen, January 26, 2024
Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028
Preliminary 2023 results in line with forecast: sales revenue in constant currencies down 16.6 percent; underlying EBITDA margin of 28.3 percent
Demand recovery in both divisions in the fourth quarter: ord......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
25.01.2024
HLN
LISTED
LSE
Yellow Wood Partners Portfolio Company Suave Brands Company Acquires ChapStick from Haleon
News Preview
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (LSE / NYSE: HLN), a global leader in consumer h...
Themefolio
Profiler
Peergroup
© Newsfile
25.01.2024
COPN
LISTED
SIX
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
News Preview
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial analysts and busine...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.01.2024
EUZ
LISTED
XETR
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
News Preview
Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.01.2024
EUZ
LISTED
XETR
Eckert & Ziegler und Full-Life Technologies unterzeichnen Actinium-225 Liefervertrag für Radiopharmazeutika der nächsten Generation
News Preview
Berlin, Deutschland und Gembloux, Belgien – 23. Januar 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) und Full-Life Technologies (Full-Life), ein in der klinischen Phase befindliches, voll integriertes und global agierendes Radiotherapeutika-Unternehmen, gaben heute bekannt, dass sie einen Vertrag über die Lieferung von Actinium-225 (Ac-225)......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2024
EVT
LISTED
XETR
Einladung zu Telefonkonferenz
News Preview
Hamburg, 22. Januar 2024:
Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) wird am Montag, den 22. Januar 2024, eine Telefonkonferenz abhalten, um eine Stellungnahme abzugeben und über die aktuelle Geschäftsentwicklung zu berichten.
Im Rahmen der Telefonkonferenz werden die Vorsitzende des Aufsichtsrats......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2024
EVT
LISTED
XETR
Invitation to Conference Call
News Preview
Hamburg, Germany, 22 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
FYB
LISTED
XETR
Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA
News Preview
Pressemitteilung // 18. Januar 2024
Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA
München – Formycon AG (FWB: FYB) gab heute bekannt, dass ihr Vermarktungspartner Coherus BioSciences, Inc. neue Verkaufszahlen zu CIMERLI®1 (Ranibizumab-eqrn) in den USA veröffentlicht hat. Demn......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
FYB
LISTED
XETR
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
News Preview
Press Release // January 18, 2024
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
16.01.2024
HLN
LISTED
LSE
Advil presents an in-game solution to fight gaming headaches
News Preview
MISSISSAUGA, ON, Jan. 16, 2024 /CNW/ - Advil is helping Canadians who love to game, play at their best with Advil Head Settings – a series of genre-based guidelines that empower gamers of all levels to fine-tune their in-game PC settings, effectively reducing the onscreen stimulation that can lead to headaches. Designed for gaming genres with the...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.01.2024
AFX
LISTED
XETR
VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA
News Preview
VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA
Die neueste Generation des ZEISS Femtosekundenlasers bietet der Refraktivchirurgie schnellere Behandlungsmöglichkeiten, größere Flexibilität und einen verbesserten klinischen Arbeitsablauf.
Jena / Deutschland | Dublin / USA | 11. Januar 2024
Heute gibt die Medizi......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.01.2024
AFX
LISTED
XETR
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
News Preview
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
DUBLIN, CA (USA) / JENA, Germany | January 11, 2024 | Carl Zeiss Meditec AG
ZEISS Medical Technology announced today tha......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
EVT
LISTED
XETR
Evotec und Crohn´s & Colitis Foundation gehen Vereinbarung zur Förderung der Wirkstoffforschung für neue IBD Therapien ein
News Preview
EVOTEC SCHLIESST SICH MIT DEM IBD THERAPEUTICS INCUBATOR PROGRAMM DER CROHN’S & COLITIS FOUNDATION ZUSAMMEN, UM DIE WIRKSTOFFFORSCHUNG FÜR ENTZÜNDLICHE DARMERKRANKUNGEN („IBD“) VORANZUTREIBEN UND NEUE THERAPIEANSÄTZE ZU IDENTIFIZIEREN
DIE KOLLABORATION NUTZT EVOTECS INTEGRIERTE END-TO-END F&E-PLATTFORM, UM DIE WIRKSTOFFFORSCHUNG FÜR ZWEI I......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
EVT
LISTED
XETR
Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
News Preview
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”)
THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR......
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
News Preview
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney diseaseSan Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endo...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
EUZ
LISTED
XETR
Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
News Preview
Berlin, Germany and Cambridge, Mass., – 8 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Ecke......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
EUZ
LISTED
XETR
Eckert & Ziegler und ARTBIO vereinbaren Partnerschaft zur Herstellung und Lieferung von Blei-212 Verbindungen
News Preview
Berlin, Deutschland und Cambridge, Massachusetts, USA, – 8. Januar 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) und ARTBIO, Inc. (ARTBIO), ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entwicklung einer neuen Klasse von Alpha-Radioliganden-Therapien (ARTs) spezialisiert hat, haben eine strategische Herstellungs- u......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
EVT
LISTED
XETR
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
News Preview
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH
Hamburg, Germany, 08 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
EVT
LISTED
XETR
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb
News Preview
WICHTIGER WISSENSCHAFTLICHER FORTSCHRITT BRINGT DIE GEMEINSAME NEUROLOGIE-PIPELINE VORAN UND LÖST EINE ZAHLUNG VON 25 MIO. $ AN EVOTEC AUS, UM DIE WEITERE FORSCHUNG VORANZUTREIBEN
Hamburg, 08. Januar 2024:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute einen Fortschritt in der strategischen P......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.01.2024
QGEN
LISTED
NYSE
QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück
News Preview
Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung
QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück
Venlo, Niederlande, 7. Januar 2024 – QIAGEN N.V. gibt Pläne bekannt, mittels eines synthetischen Aktienrückkaufs bis zu rund $300 Mio. (maximal EUR 273 Mio.) an Akti......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.01.2024
QGEN
LISTED
NYSE
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
News Preview
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
Venlo, the Netherlands, January 7, 2024 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repu......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
FYB
LISTED
XETR
Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference
News Preview
Pressemitteilung // 04. Januar 2024
Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference
München – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), ein führender unabhängiger Entwickler qualitativ hochwertiger Biosimilars hat heute bekannt gegeben, dass Formycon CEO Dr. Stefan Glombitza bei der 42. Annual J.P. Morgan Hea......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
FYB
LISTED
XETR
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
News Preview
Press Release // January 04, 2024
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
Munich, Germany – Formycon AG (FSE: FYB), a leading, independent developer of high-quality biosimilars, today announced that Formycon CEO Dr. Stefan Glombitza will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on T......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
INSP
LISTED
NYSE
Kaplan Fox & Kilsheimer LLP Notifies Inspire Medical Investors of a Class Action Lawsuit and Upcoming Deadline
News Preview
INSPIRE MEDICAL INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Inspire Medical Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY – January 4, 2024 – Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of Inspire Medical Systems, Inc. (“Inspire Medical” or the “Co......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
GXI
LISTED
XETR
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy
News Preview
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy
Subcutaneous administration of oncology drugs with digital therapy support
Integrating Gx SensAir drug delivery device with Aptar's Digital Health platform
Solution aims to improve the patient experience and quality of life of cancer patients
D......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
GXI
LISTED
XETR
Gerresheimer und Aptar Digital Health kooperieren zur Entwicklung einer integrierten Lösung für Krebstherapie
News Preview
Gerresheimer und Aptar Digital Health kooperieren zur Entwicklung einer integrierten Lösung für Krebstherapie
Subkutane Verabreichung von Krebsmedikamenten mit digitaler Therapieunterstützung
Integration der Gx SensAir Medikamentenpumpe mit der Digital Health Plattform von Aptar
Ziel: Lösung zur Verbesserung der Patientenerfahrung und Lebensqua......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
EVT
LISTED
XETR
Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
News Preview
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM
A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC
AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC
Hamburg, Germany, and Paris, France, 04 Janu......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
EVT
LISTED
XETR
Evotec und Owkin gehen K.I.-gestützte strategische Partnerschaft zur Beschleunigung der therapeutischen Pipeline in den Bereichen Onkologie und I&I ein
News Preview
PARTNERSCHAFT KOMBINIERT OWKINS FÄHIGKEITEN ZUR K.I.-GESTÜTZTEN ENTDECKUNG VON TARGETS MIT EVOTECS INTEGRIERTEN SHARED END-TO-END FORSCHUNGS- & ENTWICKLUNGS-PLATTFORM
K.I.-GESTÜTZTE PLATTFORMEN WERDEN OWKINS NEUARTIGE PROGRAMME VON DER ENTDECKUNGSPHASE IN DIE KLINISCHE ENTWICKLUNG BESCHLEUNIGEN
VEREINBARUNG UMFASST ERFOLGSABHÄNGIGE MEILENSTEI......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
EVT
LISTED
XETR
Evotec announces CEO transition
News Preview
DR WERNER LANTHALER TO STEP DOWN AS CEO
REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION
DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO
SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION
EVOTEC CONFIRMS GUIDANCE 2023
Hamburg, Germany......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
EVT
LISTED
XETR
Evotec gibt CEO-Wechsel bekannt
News Preview
DR. WERNER LANTHALER TRITT ALS VORSTANDSVORSITZENDER (CEO) ZURÜCK
STEHT DEM AUFSICHTSRAT WEITERHIN ALS STRATEGISCHER BERATER ZUR VERFÜGUNG, UM EINE REIBUNGSLOSE ÜBERGABE ZU GEWÄHRLEISTEN
DR. MARIO POLYWKA HAT ZUGESTIMMT, DAS AMT ALS CEO INTERIMISTISCH ZU ÜBERNEHMEN
SUCHE FÜR EINEN LANGFRISTIGEN CEO GESTARTET, UM DEN AUFBAU DES WELTWEIT FÜHRENDEN......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
EVT
LISTED
XETR
Evotec announces CEO transition
News Preview
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
EVT
LISTED
XETR
Evotec gibt CEO-Wechsel bekannt
News Preview
Hamburg, Deutschland, – Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass Vorstandsvorsitzender Dr. Werner Lanthaler dem Unternehmen mitgeteilt hat, dass er aus persönlichen Gründen als CEO zurücktritt und seinen Vertrag nicht bis zum Ende der aktuellen Laufz......
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2023
COPN
LISTED
SIX
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
News Preview
Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsi...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2023
SKYE
LISTED
NASDAQ
Skye Bioscience Responds to OTC Markets Promotional Policy
News Preview
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on metabolic conditions and glaucoma, has received a request by OTC Markets Group Inc. ("OTC Markets") to issue this statement about prom...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2023
SKYE
LISTED
NASDAQ
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
News Preview
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, and Tautomer Bioscience (Pty) Limited ("Tautomer"), a privately-owned biopharmaceutical company focused on addressing unmet medical...
Themefolio
Profiler
Peergroup
© Newsfile
21.11.2023
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
News Preview
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its glaucoma program at two ophthalmology-focused conferences. Company...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2023
SKYE
LISTED
NASDAQ
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
News Preview
• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg)San Diego, California--(Newsfile Corp. - October 25, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
News Preview
Los Angeles, California--(Newsfile Corp. - May 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ: ANAB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities class a...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
18.05.2020
QGEN
LISTED
NYSE
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of QIAGEN N.V. to Thermo Fisher Scientific Inc. is Fair to Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased QIAGEN N.V. (NYSE: QGEN) ("QIAGEN" or the "Company") stock prior to May 18, 2020.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2020
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 15, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Klein Law Firm LogoClass Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2020
NMMCF
LISTED
OTC
NMC Class Action Reminder: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in NMC Health Plc to Contact the Firm
News Preview
New York, New York--(Newsfile Corp. - May 8, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc (OTC Pink: NMHLY) ("NMC" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2020
NMMCF
LISTED
OTC
NMC Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In NMC Health Plc To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 7, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc ("NMC" or the "Company") (OTC Pink: NMHLY) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Far...
Themefolio
Profiler
Peergroup
© Newsfile
06.05.2020
NMMCF
LISTED
OTC
NMC Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in NMC Health Plc to Contact the Firm
News Preview
New York, New York--(Newsfile Corp. - May 6, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc (OTC Pink: NMHLY) ("NMC" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2020
NMMCF
LISTED
OTC
NMC Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In NMC Health Plc To Contact The Firm
News Preview
New York, New York--(Newsfile Corp. - May 5, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc ("NMC" or the "Company") (OTC Pink: NMHLY) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
